← Back to Search

Alkylating agents

Dose Escalation for Breast Cancer

Phase 1
Waitlist Available
Led By Heather Han, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights

Study Summary

This trial is testing if a combination of two chemotherapy drugs, eribulin and carboplatin, is safe and effective in treating advanced breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose (MTD)
Secondary outcome measures
Response Rate (RR)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose EscalationExperimental Treatment2 Interventions
Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eribulin
2012
Completed Phase 3
~2700
Carboplatin
2014
Completed Phase 3
~6670

Find a Location

Who is running the clinical trial?

Eisai Inc.Industry Sponsor
515 Previous Clinical Trials
158,952 Total Patients Enrolled
16 Trials studying Breast Cancer
2,025 Patients Enrolled for Breast Cancer
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
543 Previous Clinical Trials
135,463 Total Patients Enrolled
40 Trials studying Breast Cancer
5,761 Patients Enrolled for Breast Cancer
Heather Han, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
2013. "A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01795586.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top